NCT04175847 - A Phase I /IIa Study of RC88-ADC in Subjects with Advanced Malignant Solid Tumors | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

April 14, 2020

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumor

Interventions

DRUG

RC88

"Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration"

Trial Locations (5)

100021

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing

130021

RECRUITING

The First Hospital of Jilin University, Changchun

RECRUITING

The First Hospital of Jilin University, Changchun

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

Unknown

NOT_YET_RECRUITING

Drum Tower Hospital, Nanjing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY